Key Facts

Invested since 2018
Based in Bavaria

About the company

adivo is a biotech company generating therapeutic antibodies for companion animals, addressing the medical needs in dogs, with an upside potential for a future in care for other species.
Antibody selection is based on a novel fully synthetic, dog-specific phage display library that allows de-novo identification of antibodies to select a drug candidate with optimal properties.
adivo is a spin-off from MorphoSys AG, a leading European biopharmaceutical company. The team transfers an in-depth expertise in discovery and development of human therapeutic antibodies to the veterinary market.

Do you want to

know more about this company?

Zum Artikel

Dr. Angelika Vlachou Partner

Dr. Angelika VlachouPartner

adivo in the news

Zum Artikel

News

15. September 2023

Successful exit for HTGF: adivo joins Zoetis to bring the benefits of species-specific antibody therapies to pet owners worldwide

Zum Artikel

News

20. August 2018

Pet therapeutic antibody firm adivo announces closure of seed-financing round

More startups from Life Sciences